- Home
- VLCN vs PBM Comparison
VLCN vs PBM Comparison
Compare VLCN & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLCN
- PBM
- Stock Information
- Founded
- VLCN 2020
- PBM 1994
- Country
- VLCN United States
- PBM Canada
- Employees
- VLCN N/A
- PBM N/A
- Industry
- VLCN Auto Manufacturing
- PBM
- Sector
- VLCN Consumer Discretionary
- PBM
- Exchange
- VLCN Nasdaq
- PBM NYSE
- Market Cap
- VLCN 2.6M
- PBM 3.0M
- IPO Year
- VLCN 2021
- PBM N/A
- Fundamental
- Price
- VLCN $6.95
- PBM $4.91
- Analyst Decision
- VLCN
- PBM
- Analyst Count
- VLCN 0
- PBM 0
- Target Price
- VLCN N/A
- PBM N/A
- AVG Volume (30 Days)
- VLCN 52.1K
- PBM 114.1K
- Earning Date
- VLCN 08-05-2025
- PBM 07-07-2025
- Dividend Yield
- VLCN N/A
- PBM N/A
- EPS Growth
- VLCN N/A
- PBM N/A
- EPS
- VLCN N/A
- PBM 5.24
- Revenue
- VLCN $3,739,692.00
- PBM N/A
- Revenue This Year
- VLCN N/A
- PBM N/A
- Revenue Next Year
- VLCN N/A
- PBM N/A
- P/E Ratio
- VLCN N/A
- PBM $0.94
- Revenue Growth
- VLCN 19.70
- PBM N/A
- 52 Week Low
- VLCN $4.40
- PBM $2.93
- 52 Week High
- VLCN $448.00
- PBM $701.82
- Technical
- Relative Strength Index (RSI)
- VLCN 63.79
- PBM 53.67
- Support Level
- VLCN $5.50
- PBM $4.52
- Resistance Level
- VLCN $6.53
- PBM $5.23
- Average True Range (ATR)
- VLCN 0.62
- PBM 0.54
- MACD
- VLCN 0.18
- PBM -0.01
- Stochastic Oscillator
- VLCN 98.52
- PBM 49.93
About VLCN Volcon Inc. Common stock
Volcon Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.